015 was an expansionyear unlike any other inour history,” say execu-tives at FCB Health. “Ex-panded reach. Expandedresources. Expanded client roster. Andwith that, expanded growth.”“This has been a year when we’veexpanded our relationships with manyof our clients, which is an incredibletestament to the revolutionary and ef-fective work we’ve been doing on theirbehalf,” says Dana Maiman, presidentand CEO of FCB Health.

“At FCB Health, we’re proud of the ac-complishments of 2015,” executivessay. “We’re proud of the people we’vehired. The awards we’ve won. The busi-ness that our clients have entrustedwith us. But we’re also looking ahead.To the next innovation. The next newhire. The next big idea. Because onlywith this vision to the future can we ex-pand to even greater heights.”Agency leaders say they are “proudto share some numbers.”“We expanded our brand and clientroster with 20 new AOR assignments,”they say. “We expanded the size ofour team – by adding almost 100 newmembers to bring our total to over 800at our main office on 33rd Street, andto over 1,500 through our network.We expanded teams in social media,community management, engagementplanning, health literacy, scientificservices, content creation, and digitalproduction to be an end-to-end solu-tion for our clients. We expanded ourtrophy case being named Agency of theYear by both Med Ad News and Medi-cal Marketing and Media. We expand-ed our global footprint to include newoffices in Germany, England and Ja-pan. And lastly, we expanded our U.S.roster of agencies to now include Area
23, Neon, FCBCure, Trio, ProHealth,Mosaic, and Hudson Global.”Among the agency’s new businesswins, executives say FCB Health ex-panded its relationship with manycurrent clients, including adding AORassignments from Novartis for multi-ple sclerosis, Teva for women’s health,AbbVie for endometriosis, Amgenfor bone health, oncology and cardio-vascular, Galderma for rosacea, andassignments from new clients includ-ing Valeant for psoriasis and Lexi-con for oncology/rare disease.

“When your current clients awardyou additional business, it’s validationthat the entire team is adding valueevery day,” says Mike Guarino, execu-tive VP, chief strategy officer. “Anotherdivision of our business that has seenenormous growth has been our brand-ing team, winning over 20 new assign-ments in the past year.”Executives also say the agency hadan “incredible” year launching newproducts and new campaigns for exist-ing clients. On the consumer side, FCBHealth launched new work for Dys-port and Restylane Silk, Kerydin,Linzess, Myrbetriq, Prolia, PlanB, Paragard, Spiriva, NamendaXR, and Namzaric. On the profes-sional side, new work and launchesinclude Evotaz, Novartis for advancedBCC, Savaysa, Entresto, Colcrys,Uloric and many others.

“At one point in 2015, we had eight
DTC campaigns on the air or online at
the same time,” says Rich Levy, executive VP, chief creative officer. “
Watching TV was like watching our agency
reel. We’re very proud that many of
our clients trust us with both their HCP
and DTC businesses. Today almost 35
percent of our assignments are integrated with the majority including digital as well.”

March 2015 saw further expansion
with the realignment of FCBCure and
Trio under the FCB Health Network.
FCBCure, currently going through a
multimillion dollar renovation of its
physical space, welcomed a new management team over the summer with
Christine Finamore and Tom Millar as
managing directors.

Last year also saw the implementation of the agency’s “Co-Op” creation
process across the entire network. “The
model emphasizes teams over departments, personal interactions over indirect communication,” executives say.
“This allows our teams to be more agile responding to change versus stuck
adhering to a rigid structure. The goal
is to make a seamless process, which
works within a medical, legal, and regulatory environment, yet be able to
create the best possible product. The
results have been staggering – with
faster turnaround, simplified communication and happier team members.”